Finland· FI-REL-REL61029
Prolastina
A alfa1 antitrypsin product containing alpha-1 proteinase inhibitor, registered in Finland by Grifols Deutschland GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Alfa1 antitrypsin is registered in 11 of 19 countries.
Countries holding a registration under ATC B02AB02 (alfa1 antitrypsin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Alfa1 antitrypsin · ATC B02AB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of alfa1 antitrypsin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alfa1 antitrypsin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$261.83
The record
At a glance
Fimea (Finland)- Active substance
- Alpha-1 Proteinase inhibitor
- Manufacturer
- Grifols Deutschland GmbH
- Country
- Finland (FI)
- ATC code
- B02AB02
- ATC class
- Alfa1 antitrypsin
- Defined daily dose
- 0.6 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alfa1 antitrypsin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayProlastinaGrifols Deutschland GmbH
- SwedenProlastina 4000 mg Pulver och vätska till infusionsvätska, lösningGrifols Deutschland GmbH
- IrelandProlastin 4000 mg, powder and solvent for solution for infusionGrifols Deutschland GmbH
- PolandRespreezaCSL Behring GmbH
- FranceALFALASTIN 33,33 mg/mL, poudre et solvant pour solution injectableLFB-BIOMEDICAMENTS
- CzechiaPROLASTINAGrifols Deutschland GmbH, Frankfurt
- IcelandRespreezaCSL Behring GmbH*
- United StatesGLASSIATakeda Pharmaceuticals America, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Prolastin
- Belgium · Pulmolast
- Cyprus · Prolastina
- Czechia · Prolastina
- Germany · Prolastin
- Denmark · Prolastina
- Spain · Prolasplan, Prolastina
- France · Alfalastin, Prolastin
- Greece · Prolastin
- Croatia · Prolastina
- Ireland · Prolastin
- Iceland · Respreeza
- Italy · Plitalfa, Prolastin
- Liechtenstein · Respreeza
- Netherlands · Prolastin
- Norway · Prolastina, Respreeza
- Poland · Prolastin, Prolastin, 4000 Mg
- Portugal · Prolastin
- Sweden · Prolastina
- Slovakia · Prolastina
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c805505b-081a-4c67-b067-1370cc7918ed GET /v1/drugs/c805505b-081a-4c67-b067-1370cc7918ed?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.6",
"form": "infuusiokuiva-aine ja liuotin, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "g",
"strength": "4000 mg",
"atc_label": "alfa-1-antitrypsiini",
"ma_number": "41968",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL61029",
"authorised_at": "2023-11-24"
}See everything about alfa1 antitrypsin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.